ARS Pharma Sales Jump 3,040% in Q2
ARS Pharmaceuticals ( NASDAQ:SPRY ) , the biopharma company developing needle-free allergy treatments, released its second-quarter 2025 results on August 13, 2025. The most significant takeaway from the release was a major GAAP revenue beat, as total GAAP revenue climbed to $15.7 million versus ...
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q2 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -12.20% and +3.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics ( CORT ) Tops Q2 Earnings Estimates
Corcept (CORT) delivered earnings and revenue surprises of +26.09% and -4.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help ARS Pharmaceuticals, Inc. ( SPRY ) Maintain Its Recent Price Strength
ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Catalyst Pharmaceutical ( CPRX ) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ARS Pharmaceuticals, Inc. ( SPRY ) to Report a Decline in Earnings: What to Look Out for
ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EURneffy® ( adrenaline nasal spray ) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions ( anaphylaxis )
EURneffy ( neffy® in the U.S. ) offers a new delivery method for adrenaline in the U.K. for adults and children ( >30 kg ) living with severe allergic reactions ...
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
ALK ( ALKB:DC / OMX: ALK B ) today announced that the Medicines and Healthcare Products Regulatory Agency ( MHRA ) has approved EURneffy® 2 mg in the United Kingdom ( UK ) for anaphylaxis treatment of adults and children ( ≥30 kg ) .
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
Inside Information ...
ARS Pharmaceuticals, Inc. ( SPRY ) is a Great Momentum Stock: Should You Buy?
Does ARS Pharmaceuticals, Inc. (SPRY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. ( SPRY ) : Can the Stock Really Move This High?
The mean of analysts' price targets for ARS Pharmaceuticals, Inc. (SPRY) points to a 78.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes ARS Pharmaceuticals, Inc. ( SPRY ) a Good Fit for 'Trend Investing'
ARS Pharmaceuticals, Inc. (SPRY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
ALK ( ALKB:DC / OMX: ALK B ) today announced the first market launch of EURneffy® 2 mg ( the trade name for neffy® in the EU ) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children ...
Jim Cramer: All Aboard Union Pacific, 'Tired' Of Orphan Drugs - GitLab ( NASDAQ:GTLB ) , BioMarin Pharmaceutical ( NASDAQ:BMRN )
"I was prepared for disappointment and I got it," Cramer on GitLab. "I think it's a really good stock to own," Cramer on Union Pacific. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - ARS Pharmaceuticals ( NASDAQ:SPRY )
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. ( Nasdaq: SPRY ) , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard ...
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. ( Nasdaq: SPRY ) , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard ...
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q1 Loss, Lags Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® ( epinephrine nasal spray ) - ARS Pharmaceuticals ( NASDAQ:SPRY )
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increases neffy promotional reach to nearly 20,000 healthcare providers, including key pediatricians
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® ( epinephrine nasal spray )
$7.8 million in total neffy U.S. net product revenue in first quarter of ...
ARS Pharmaceuticals' neffy® ( epinephrine nasal spray ) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - ARS Pharmaceuticals ( NASDAQ:SPRY )
The availability of neffy 1 mg extends protection to younger, school-aged children-who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 ( if eligible ) in preparation for summer travel and back-to-school
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® ( epinephrine nasal spray ) to Additional U.S. Pediatricians - Alaska Air Gr ( NYSE:ALK ) , ARS Pharmaceuticals ( NASDAQ:SPRY )
Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® ( epinephrine nasal spray ) to Additional U.S. Pediatricians
Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States ...
ALK enters into neffy® co-promotion agreement in the USA
ALK ( ALKB.DC / OMX: ALK B ) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. ( "ARS Pharma", NASDAQ: SPRY ) to co-promote the neffy® adrenaline ( epinephrine ) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close ...
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - China Liberal Education ( NASDAQ:CLEU ) , Capricor Therapeutics ( NASDAQ:CAPR )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Jabil Inc. JBL rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 guidance.
ARS Pharmaceuticals, Inc. ( SPRY ) Q4 Earnings and Revenues Beat Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of 1,400% and 273.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment - ARS Pharmaceuticals ( NASDAQ:SPRY )
FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - ARS Pharmaceuticals ( NASDAQ:SPRY )
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children ...
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences - ARS Pharmaceuticals ( NASDAQ:SPRY )
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
Company to Host Conference Call on March 20 at 8:30 a.m. ET ...
ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® ( Epinephrine Nasal Spray ) to National Formularies, Further Expanding Coverage for Patients
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to ...
Allergy Treatment Market Size is Projected to Reach USD 64.65 billion by 2033, Growing at a CAGR of 6.46%: Straits Research
New York, United States, Jan. 22, 2025 ( GLOBE NEWSWIRE ) -- Many of the population suffer from allergies, frequently associated with a low quality of life characterized by the constant fear of allergen-induced reactions. Allergies hinder a person's productivity, so allergic conditions must be ...
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - ARS Pharmaceuticals ( NASDAQ:SPRY )
School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® ( epinephrine nasal spray ) 2 mg for undesignated use meets applicable state law requirements Interested schools can visit neffy.com/community-programs to apply
ARS Pharmaceuticals Announces neffy® ( Epinephrine Nasal Spray ) is available on Express Scripts Commercial National Formularies - ARS Pharmaceuticals ( NASDAQ:SPRY )
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals Announces neffy® ( Epinephrine Nasal Spray ) is available on Express Scripts Commercial National Formularies
Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions ...
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - ARS Pharmaceuticals ( NASDAQ:SPRY )
SAN DIEGO, Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. SPRY, a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the ...
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
Licensing partners in key Asia Pacific countries have filed for approval of neffy ( epinephrine nasal spray ) 2 mg with regulatory agencies Licensing partners in key Asia Pacific countries have filed for approval of neffy ( epinephrine nasal spray ) 2 mg with regulatory agencies ...
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - ARS Pharmaceuticals ( NASDAQ:SPRY )
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons ( four single use doses ) of neffy® ( epinephrine nasal spray ) 2mg for use in emergency treatment of allergic reactions including anaphylaxis
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q3 Loss, Misses Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -11.11% and 8.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy® ( epinephrine nasal spray ) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA. PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other ...
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 - ARS Pharmaceuticals ( NASDAQ:SPRY )
On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. SPRY. The agreement grants ALK exclusive global rights to the neffy adrenaline ( epinephrine ) nasal spray, except in the U.S., Australia, New Zealand, Japan, and China.
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products ...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions ( anaphylaxis )
ALK ( ALKB:DC / OMX: ALK B ) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. ( "ARS Pharma", NASDAQ: SPRY ) . The agreement grants ALK exclusive global rights to the neffy® adrenaline ( epinephrine ) nasal spray, with exception of the ...
GoodRx ( GDRX ) Q3 2024 Earnings Call Transcript
GDRX earnings call for the period ending September 30, 2024.
Wall Street Analysts Think ARS Pharmaceuticals, Inc. ( SPRY ) Could Surge 67.56%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 67.6% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology ( ACAAI ) Annual Scientific Meeting
SAN DIEGO, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. ( Nasdaq: SPRY ) , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that ...
Wall Street Analysts Believe ARS Pharmaceuticals, Inc. ( SPRY ) Could Rally 76.79%: Here's is How to Trade
The consensus price target hints at a 76.8% upside potential for ARS Pharmaceuticals, Inc. (SPRY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
SAN DIEGO, Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. ( Nasdaq: SPRY ) , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its ...
